BM
bioMérieux S.A.
BMXXY · OTC
$8.50 -2.30% (-$0.20)
1M -4.06%
Market Cap 8.62B €
P/E Ratio 22.58x
Div. Yield 1.34%
ROE 9.24%
Bulios Fair Price
$7.66
9.9% downside
Current Price
$8.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BMXXY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
9/9Valuation
71 /100
Cheap EV/EBITDA 8.87x
P/S 2.21x
P/B 2.10x
Growth
43 /100
Stable Rev. growth 2.89%
FCF growth 32.18%
Book val. growth 4.39%
Profitability
71 /100
Strong Net margin 9.77%
Op. margin 13.79%
FCF margin 11.13%
Quality
50 /100
Average ROE 9.24%
ROA 6.85%
Asset turnover 0.70x
Debt
100 /100
Low Current ratio 2.39x
Net debt/EBITDA -0.11x
Debt/Equity 0.11x
Stability
93 /100
Stable Rev. volatility 5.07%
EPS volatility 21.42%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BMXXY
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Pierre Boulud
Employees
15,078
Headquarters
Marcy l'Étoile